Relationship among insulin-like growth factor-I, blood metabolites and postpartum ovarian function in dairy cows

Studies on substantially increased proteins in follicular fluid of bovine ovarian follicular cysts using 2-D PAGE and MALDI-TOF MS

BACKGROUND

The objective of this study was to identify substantially increased proteins in bovine cystic follicular fluid (FF) in order to clarify the pathology and etiology of bovine ovarian follicular cysts (BOFC).

METHODS

Proteins in normal and cystic FF samples were subjected to two-dimensional polyacrylamide gel electrophoresis (2-D PAGE) and were compared using silver stained gel images with PDQuest image analysis software. Peptides from these increased spots were analyzed by matrix assisted laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF MS), and were identified based on the NCBI database by a peptide mass fingerprinting method.

RESULTS

Comparative proteomic analysis showed 8 increased protein spots present in cystic FF. MS analysis and database searching revealed that the increased proteins in cystic FF were bovine mitochondrial f1-atpase (BMFA), erythroid associated factor (EAF), methionine synthase (MeS), VEGF-receptor, glyceraldehydes 3-phosphate dehydrogenase (GAPDH), heat shock protein 70 (HSP70), beta-lactoglobulin (BLG) and succinate dehydrogenase Ip subunit (SD).

CONCLUSION

Our results suggest that these proteins are overexpressed in BOFC, and that they may play important roles in the pathogenesis of BOFC. Furthermore, these proteins in the FF could be useful biomarkers for BOFC.

Immune-enhancing effects of growth hormone-releasing hormone delivered by plasmid injection and electroporation

Growth hormone-releasing hormone (GHRH) is a hypothalamic hormone with both direct and indirect functions in the maintenance of immune status under physiological and pathological conditions. In this study, 52 Holstein heifers were evaluated for the effects of a plasmid-mediated GHRH treatment on their immune function and on the morbidity and mortality of treated animals. In the third trimester of pregnancy, 32 heifers received 2.5 mg of a myogenic GHRH-expressing plasmid by intramuscular injection followed by electroporation, while 20 heifers were used as controls. No adverse effects were associated with either the plasmid delivery or GHRH expression. At 18 days after plasmid administration, GHRH-treated animals had increased numbers of CD2(+) alphabeta T-cells (P < 0.004), CD25(+)CD4(+) cells (P < 0.0007), and CD4(+)CD45R(+) cells (P < 0.016) compared to controls. These increases were maintained long term after treatment and correlated with plasmid expression. At 300 days post-GHRH therapy, CD45R(+)/CD45R0(-) naïve lymphocytes were significantly increased in frequency (P < 0.05). Natural killer lymphocytes (CD3(-)CD2(+)) were also increased. As a consequence of improved health status, body condition scores of treated animals improved (3.55 vs. 3.35, P < 0.0001). Hoof pathology was also reduced with treatment. The mortality of heifers was decreased (3% vs. 20% in controls, P < 0.003). Collectively, these results indicate that the myogenic GHRH plasmid can be successfully electrotransferred into a 500-kg mammal and expressed for prolonged periods of time, ensuring physiological levels of GHRH. The plasmid injection followed by electroporation could prove an efficient method for the systemic production of therapeutic proteins and may provide a useful means for basic research in relevant animal models.